Evidence map›Paper›PMID 30838036›Full record

ArticleFrontiers in genetics2019

CaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic Features.

Vinay K Kartha, Paola Sebastiani, Joseph G Kern, Liye Zhang, Xaralabos Varelas, Stefano Monti

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Vinay K KarthaBioinformatics Program, Boston University, Boston, MA, United States.
Paola SebastianiBioinformatics Program, Boston University, Boston, MA, United States.
Joseph G KernDepartment of Biochemistry, Boston University School of Medicine, Boston, MA, United States.
Liye ZhangSchool of Life Sciences and Technology, ShanghaiTech University, Shanghai, China.
Xaralabos VarelasDepartment of Biochemistry, Boston University School of Medicine, Boston, MA, United States.
Stefano MontiBioinformatics Program, Boston University, Boston, MA, United States.
Boston University · USShanghaiTech University · CN

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Defining epithelial polarity cues that direct cell fateR01HL124392 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI VARELAS, XARALABOS · 2014 to 2024
$4.5M
High-throughput multi-omic profiling of human oral squamous cell carcinoma (OSCC) to elucidate mechanisms of tumor initiation and progressionF31DE025536 · NIDCR · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI KARTHA, VINAY KRISHNA · 2016 to 2018
$78k
NCATS NIH HHS UL1 TR001430NHLBI NIH HHS R01 HL124392NIDCR NIH HHS F31 DE025536
6 · The paper itself

Abstract

The identification of genetic alteration combinations as drivers of a given phenotypic outcome, such as drug sensitivity, gene or protein expression, and pathway activity, is a challenging task that is essential to gaining new biological insights and to discovering therapeutic targets. Existing methods designed to predict complementary drivers of such outcomes lack analytical flexibility, including the support for joint analyses of multiple genomic alteration types, such as somatic mutations and copy number alterations, multiple scoring functions, and rigorous significance and reproducibility testing procedures. To address these limitations, we developed Candidate Driver Analysis or CaDrA, an integrative framework that implements a step-wise heuristic search approach to identify functionally relevant subsets of genomic features that, together, are maximally associated with a specific outcome of interest. We show CaDrA's overall high sensitivity and specificity for typically sized multi-omic datasets using simulated data, and demonstrate CaDrA's ability to identify known mutations linked with sensitivity of cancer cells to drug treatment using data from the Cancer Cell Line Encyclopedia (CCLE). We further apply CaDrA to identify novel regulators of oncogenic activity mediated by Hippo signaling pathway effectors YAP and TAZ in primary breast cancer tumors using data from The Cancer Genome Atlas (TCGA), which we functionally validate

Indexed as

CCLEoncogenic driver analysisR packagestepwise searchTCGA

Identifiers

PMID30838036
PMCPMC6390206
OpenAlexW2949124738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.